CAMBRIDGE, Mass.–(BUSINESS WIRE)–TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of positive interim Phase 1 data for its intravenous formulation of 131I-TM-601 in recurrent glioma at the American Society for Therapeutic Radiology and …
Trending at Lumira Ventures
Avalon Pharmaceuticals files for $50 million shelf
Learn More-External Link
Pharmasset says R7128 has received fast track designation from the FDA…
R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset’s collaboration with Roche. As noted on 3-Oct, Pharmasset has commenced dosing in a 28-day Phase 1 clinical trial to …
New Airway Stent Improves Quality of Life in Cancer Patients: Presented at CHEST
Learn More-External Link
Archemix sees IPO of 4.5 mln shares at $12-$14 per share
Learn More-External Link
Avalon Pharma Says AvalonRx Identifies Potent Selective Inhibitors…
Learn More-External Link
Transmolecular appoints Nicolaides as board chair
Learn More-External Link
Pharmasset’s Hepatitis C Drug Has A Promising Future
Learn More-External Link
Natus Medical to Acquire Excel-Tech Ltd.
Learn More-External Link
Pharmasset Accesses up to $30 Million of Working Capital
Learn More-External Link
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Learn More-External Link
Argos Therapeutics’ Scientific Founder Ralph Steinman, M.D., Receives…
Learn More-External Link
Replidyne’s Investigational Antibacterial Agent REP3123 Prevents Toxin Production…
Learn More-External Link
MAKO Surgical Announces Filing Of Registration Statement With SEC For IPO
Learn More-External Link
MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
Learn More-External Link